12 Best Psychedelic Stocks to Buy in 2025

Page 2 of 10

9. Atai Life Sciences N.V. (NASDAQ:ATAI)

Number of Hedge Fund Holders: 14 

Atai Life Sciences N.V. (NASDAQ:ATAI) is a clinical-stage biopharmaceutical company focused on developing psychedelic-inspired treatments for mental health disorders like depression, anxiety, and addiction. While it doesn’t yet sell products, the company generates revenue through research, clinical trial support, and licensing agreements. What sets Atai Life Sciences N.V. (NASDAQ:ATAI) apart is its decentralized drug development model, where it creates and acquires businesses focused on specific psychedelic compounds, allowing for a diversified portfolio and reduced risk.

As of September 30, 2024, Atai Life Sciences N.V. (NASDAQ:ATAI) reported a strong cash position of $101.0 million, providing an operational runway into 2026. The company reduced its R&D expenses to $12.4 million in Q3 2024, down from $13.3 million in Q3 2023, and also lowered its general and administrative expenses to $10.3 million from $13.6 million. However, the corporation posted a net loss of $26.3 million for Q3 2024, compared to a net income of $44.2 million in Q3 2023.

Recognized among the best psychedelic stocks, Atai Life Sciences N.V. (NASDAQ:ATAI) is making significant progress in its clinical pipeline. VLS-01, a DMT treatment for treatment-resistant depression, has received FDA clearance and expects to begin Phase 2 studies by the end of 2024. EMP-01, an R-MDMA treatment for social anxiety disorder, also anticipates its Phase 2 trial around the same time. RL-007, targeting cognitive impairment in schizophrenia, is in Phase 2b, with results expected in mid-2025. Additionally, Atai Life Sciences N.V. (NASDAQ:ATAI) completed the acquisition of IntelGenx Corp., enhancing its drug delivery capabilities for VLS-01’s buccal film DMT program.

Page 2 of 10